SYDNEY, AU, Feb 3, 2023 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific focused biotech specialist CRO and recipient of the Asia Pacific Cell & Gene Therapy […]
SYDNEY, AU, Sep 15, 2022 – (ACN Newswire via SEAPRWire.com) – Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award […]
MADISON, WI, Jul 27, 2022 – (JCN Newswire via SEAPRWire.com) – UW Health has selected Hitachi, Ltd. (TSE:6501, “Hitachi”) to provide the infrastructure to support proton therapy at UW Health […]
TOKYO, Feb 2, 2022 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) has announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical […]
TOKYO, Nov 22, 2021 – (JCN Newswire via SEAPRWire.com) – Hitachi, Ltd. (TSE: 6501) announced today that it has been selected by the University of Tsukuba to provide Hitachi’s proton […]
SYDNEY, Oct 14, 2021 – (ACN Newswire via SEAPRWire.com) – Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment […]
TOKYO, Jun 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy […]
